English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/65458
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorAguilera, Isabel-
dc.contributor.authorSousa, José M.-
dc.contributor.authorPraena-Fernández, Juan Manuel-
dc.contributor.authorGómez-Bravo, Miguel A.-
dc.contributor.authorNúñez-Roldán, Antonio-
dc.date.accessioned2013-01-30T11:07:35Z-
dc.date.available2013-01-30T11:07:35Z-
dc.date.issued2011-
dc.identifierdoi: 10.1111/j.1399-0012.2010.01221.x-
dc.identifierissn: 0902-0063-
dc.identifier.citationClinical Transplantation 25(2): 207-212 (2011)-
dc.identifier.urihttp://hdl.handle.net/10261/65458-
dc.description.abstractIn 2004, we defined the genetic mismatch in the glutathione S-transferase T1 (GSTT1) gene positive donor/null recipient as a risk factor to develop de novo immune hepatitis (IH) after liver transplant (LT), which is always associated with production of donor-specific anti-GSTT1 antibodies. However, there are several unresolved questions, such as why some of these patients produce antibodies, why others do not and why not all of the patients with antibodies develop the disease. The aim of this study was to evaluate the influence of several variables in the production of anti-GSTT1 antibodies and/or de novo IH. The study group included 35 liver-transplanted patients. The number of patients not producing antibodies was significantly higher in the group treated with Tac-based immunosuppression compared with the CsA-based group (94.1% vs. 5.9%, p=0.001). Additionally, a protective effect of the Tac-based therapy vs. the CsA-based therapy was observed with regard to development of de novo IH (80.8% vs. 19.2%, p=0.003). In conclusion, the choice of calcineurin inhibitor may influence the development of de novo IH mediated by anti-GSTT1 antibodies. © 2010 John Wiley & Sons A/S.-
dc.description.sponsorshipThe authors thank L. Barrera from the Liver Transplant Unit for her assistance with data resources and F. Gavila´n for providing photographs for Fig. 1. This study was supported by grants from Fondo de Investigaciones Sanitarias, Ministerio de Sanidad y Consumo, Spain: FIS 02/3072, FIS 05/0374, FIS 05/0733, Junta de Andalucı´a PI- 0332, CTS 2886 and European Community FEDER funds.-
dc.language.isoeng-
dc.publisherBlackwell Publishing-
dc.rightsclosedAccess-
dc.titleChoice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation-
dc.typeartículo-
dc.identifier.doihttp://dx.doi.org/10.1111/j.1399-0012.2010.01221.x-
dc.date.updated2013-01-30T11:07:35Z-
dc.description.versionPeer Reviewed-
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.